STOCKHOLM , May 14, 2025 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) ("Neonode" or the "Company") today reported financial results for the three months ended March 31, 2025. FINANCIAL SUMMARY FOR THE QUARTER ENDED MARCH 31, 2025: Revenues from continuing operations of $0.5 million, a decrease of 37.0% compared to the same period in the prior year.

The Gap, Inc. has continued to show turnaround progress. The Old Navy and Gap brands are showing increased relevance, and Gap's cost focus is expanding margins significantly. The upcoming Q1 report should show similar underlying trends. On the other hand, consumer weakness amid tariff uncertainty pressures the industry outlook. Based on turnaround progress, GAP stock remains undervalued. I estimate 42% upside to $36.1.

Saudi Arabia's plan to invest $20 billion in U.S. artificial-intelligence data centers and energy infrastructure creates big opportunities for AI stocks.

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.

TELUS Health combines digital-first innovation with Workplace Options' Employee and Family Assistance Program to transform employee wellbeing solutions GTCR to invest US$200 million as part of the acquisition, bringing strategic healthcare industry expertise to accelerate TELUS Health's global growth and innovation VANCOUVER, BC and TORONTO , May 14, 2025 /PRNewswire/ - TELUS Corporation ("TELUS") (TSX: T) (NYSE: TU) today announced a strategic partnership with GTCR, a leading private equity investor with extensive expertise across the healthcare landscape, supporting TELUS Health's recently announced acquisition of Workplace Options. Last week, TELUS Health announced the acquisition of Workplace Options for cash of approximately …

NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy.

EGY's plans in Cote d'Ivoire involve the refurbishment of the FPSO at the Baobab field in Block CI-40. In Gabon, EGY is gearing up for the 2025/2026 drilling program.

STRT, EWCZ and SWX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 14, 2025.

The US DoC has scrapped the AI Diffusion export controls, removing a major regulatory overhang and reigniting Nvidia's global Sovereign AI ambitions. Nvidia's new multi-billion dollar deals in the Middle East, especially with Saudi Arabia, could add an estimated $63B in high-margin revenue. Nvidia's ex-USA business is rapidly accelerating, and these catalysts are not yet reflected in consensus analyst forecasts or current valuation multiples.

Kornit Digital (KRNT) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.11 per share a year ago.

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company's ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations

LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco announces that a securities class action alleging violations of the Securities Exchange Act of 1934 has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI), and others, on behalf of persons or entities who purchased or otherwise acquired publicly traded Compass securities between May 1, 2024, and May 7, 2025, inclusive (the “Class Period”). The case is styled, Matthews v. Compass Group Diversified Holdings, LLC, et. al, No. 25-cv-00981 (C.D. Cal.).

SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) -- Primech Holdings Limited ("Primech" or the "Company") (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced that it has received notice from the Nasdaq Stock Market ("Nasdaq") on May 13, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet.

After the health insurer pulled its outlook for the year, analysts rushed to cut their predictions on the stock.